feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Guernsey Trial: Weight Loss Jabs to Aid 300

Guernsey Trial: Weight Loss Jabs to Aid 300

30 Jan

•

Summary

  • Up to 300 people will join a two-year weight loss jab trial.
  • Medication mimics natural hormones to control appetite.
  • Trial aims to improve health and potentially reduce costs.
Guernsey Trial: Weight Loss Jabs to Aid 300

A significant weight loss medication trial is set to commence in Guernsey, involving up to 300 participants over a two-year period. This trial could pave the way for the weight loss jabs to become available via prescription, according to government announcements.

President of health and social care, George Oswald, a medical doctor, emphasized the medication's efficacy, stating it delivers results much more quickly and effectively than conventional methods. Currently, the drug is used to treat type 2 diabetes patients.

The trial, managed by Public Health, will assess the medication's health improvement benefits. Oswald expressed hope that positive results would encourage the extension of the drug's rollout. He noted that obesity, particularly morbid obesity, affects numerous health conditions, including cancer and osteoarthritis, and the medication's appetite-controlling properties could significantly mitigate these risks.

trending

India US trade tariffs slashed

trending

Salesforce lays off 1000

trending

Dhakshineswar Suresh Davis Cup hero

trending

CBSE board exams: key details

trending

US lowers Bangladesh tariffs

trending

iPhone 17 Croma Valentine's sale

trending

Herb may reverse hair loss

trending

Netherlands face prepared Namibia

trending

Jana Nayagan movie court case

While the jabs may enhance quality of life and offer cost savings, Oswald cautioned they should complement, not replace, preventative measures like healthy eating and increased exercise.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The trial aims to evaluate the effectiveness of weight loss jabs in improving health for up to 300 participants over two years, potentially leading to prescription availability.
The medication mimics a natural hormone that controls appetite, helping individuals manage their weight.
By controlling obesity, the medication could significantly impact various health issues such as cancer, osteoarthritis, and neurodevelopmental conditions like dementia.

Read more news on

Healthside-arrow

You may also like

Obesity Fuels Deadly Infections: UK Study Warns

18 hours ago • 4 reads

article image

Brits Flunking Fibre: 96% Fall Short

2 Feb • 53 reads

article image

Gallbladder Removals Spike Amid Weight Injection Use

30 Jan • 64 reads

article image

New Screening Halts T1 Diabetes 'Crash Landings'

21 Jan • 116 reads

article image

Obesity Pill: Cheaper, Needle-Free Future for UK?

15 Jan • 168 reads

article image